PE20120630A1 - Inmunoconjugados dirigidos - Google Patents
Inmunoconjugados dirigidosInfo
- Publication number
- PE20120630A1 PE20120630A1 PE2012000192A PE2012000192A PE20120630A1 PE 20120630 A1 PE20120630 A1 PE 20120630A1 PE 2012000192 A PE2012000192 A PE 2012000192A PE 2012000192 A PE2012000192 A PE 2012000192A PE 20120630 A1 PE20120630 A1 PE 20120630A1
- Authority
- PE
- Peru
- Prior art keywords
- group
- union
- terminal
- effecting
- antigen
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
REFERIDA A UN INMUNOCONJUGADO QUE COMPRENDE: a) UN PRIMER GRUPO EFECTOR DE UNA CADENA Y b) UN PRIMER Y UN SEGUNDO GRUPO DE UNION A ANTIGENO SELECCIONADO DE UN Fv Y UN Fab, DONDE DICHO PRIMER GRUPO EFECTOR COMPARTE UN ENLACE PEPTIDICO AMINO-TERMINAL O CARBOXI-TERMINAL CON DICHO PRIMER GRUPO DE UNION A ANTIGENO Y EN EL QUE DICHO SEGUNDO GRUPO DE UNION A ANTIGENO COMPARTE UN ENLACE PEPTIDICO AMINO-TERMINAL O CARBOXI-TERMINAL CON EL PRIMER GRUPO EFECTOR O EL PRIMER GRUPO DE UNION A ANTIGENO. TAMBIEN ESTA REFERIDA A UN POLINUCLEOTIDO, UNA CELULA HUESPED Y UNA COMPOSICION FARMACEUTICA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13458409P | 2009-08-17 | 2009-08-17 | |
EP10162410 | 2010-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120630A1 true PE20120630A1 (es) | 2012-05-26 |
Family
ID=43033282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000192A PE20120630A1 (es) | 2009-08-17 | 2010-08-13 | Inmunoconjugados dirigidos |
Country Status (22)
Country | Link |
---|---|
US (1) | US8945571B2 (es) |
EP (1) | EP2467165B1 (es) |
JP (1) | JP5764127B2 (es) |
KR (2) | KR20120053042A (es) |
CN (1) | CN102573922B (es) |
AR (1) | AR077879A1 (es) |
AU (1) | AU2010285071A1 (es) |
CA (1) | CA2769619C (es) |
CO (1) | CO6430436A2 (es) |
CR (1) | CR20120042A (es) |
EC (1) | ECSP12011685A (es) |
ES (1) | ES2534085T3 (es) |
HK (1) | HK1169318A1 (es) |
IL (1) | IL217844A0 (es) |
MA (1) | MA33717B1 (es) |
MX (1) | MX2012002014A (es) |
PE (1) | PE20120630A1 (es) |
RU (1) | RU2583876C2 (es) |
SG (1) | SG178443A1 (es) |
TW (1) | TW201119672A (es) |
WO (1) | WO2011020783A2 (es) |
ZA (1) | ZA201200767B (es) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
WO2011040973A2 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
PT2603530T (pt) | 2010-08-13 | 2018-01-09 | Roche Glycart Ag | Anticorpos anti-fap e métodos de utilização |
CN103168049B (zh) * | 2010-08-13 | 2015-10-07 | 罗切格利卡特公司 | 抗生腱蛋白-c a2抗体及使用方法 |
AU2015213405B2 (en) * | 2010-08-13 | 2017-08-03 | Roche Glycart Ag | Anti-FAP antibodies and methods of use |
CN103476433A (zh) * | 2011-02-10 | 2013-12-25 | 罗切格利卡特公司 | 改良的免疫疗法 |
MY190604A (en) | 2011-02-10 | 2022-04-27 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
CA2844141A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Anti-mcsp antibodies |
ES2762179T3 (es) * | 2011-09-26 | 2020-05-22 | Philogen Spa | Terapia de combinación de inmunocitocinas |
CA2861927C (en) | 2012-01-20 | 2021-01-26 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
ES2848732T3 (es) * | 2012-08-07 | 2021-08-11 | Roche Glycart Ag | Inmunoterapia mejorada |
SG11201408526SA (en) | 2012-08-08 | 2015-03-30 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof |
CN109705218B (zh) | 2012-08-09 | 2022-07-19 | 罗切格利卡特公司 | Asgpr抗体及其用途 |
US9561275B2 (en) | 2012-09-14 | 2017-02-07 | The Johns Hopkins University | Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
AU2014292371B2 (en) | 2013-07-18 | 2018-03-29 | Centre Hospitalier Regional Universitaire De Montpellier | Fusokines involving cytokines with strongly reduced receptor binding affinities |
ES2714504T3 (es) * | 2013-07-19 | 2019-05-28 | Vib Vzw | Miembros de la familia il-1 modificados dirigidos |
KR102268688B1 (ko) | 2013-07-19 | 2021-06-24 | 브이아이비 브이지더블유 | 표적화된 변형된 tnf 패밀리 구성원 |
WO2015007520A1 (en) | 2013-07-19 | 2015-01-22 | Vib Vzw | Targeting of cytokine antagonists |
CA2923829A1 (en) | 2013-09-10 | 2015-03-19 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
EP3099332A4 (en) | 2014-01-29 | 2017-06-21 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
CN106456795A (zh) * | 2014-03-03 | 2017-02-22 | 辛塔医药品有限公司 | 靶向治疗学 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
WO2015143004A1 (en) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
EP3139955B1 (en) * | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusion proteins for treating cancer and related methods |
SI3489256T1 (sl) | 2014-11-14 | 2021-08-31 | F. Hoffmann-La Roche Ag | Molekule, ki vežejo antigen in vsebujejo trimer ligandov iz družine TNF |
GB201500875D0 (en) * | 2015-01-19 | 2015-03-04 | Philogen Spa | Antibodies for treatment and diagnosis |
EP3256484B1 (en) * | 2015-02-13 | 2021-06-23 | Agency For Science, Technology And Research | Non-membrane disruptive p53 activating stapled peptides |
CN107207579B (zh) * | 2015-03-31 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
RU2018124307A (ru) | 2015-12-04 | 2020-01-14 | Новартис Аг | Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции |
CN106349393B (zh) * | 2015-12-21 | 2020-10-30 | 合肥立方制药股份有限公司 | 一种增强抗体药物稳定性的结构 |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
DK3411398T3 (da) | 2016-02-05 | 2024-06-24 | Orionis Biosciences BV | Målrettede terapeutiske midler og anvendelse heraf |
WO2017153402A1 (en) | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding single domain antibodies |
CA3023883A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
BR112019002394B1 (pt) | 2016-08-10 | 2021-12-21 | Ajou University Industry-Academic Cooperation Foundation | Proteína heterodimérica fundida com fc e seu uso |
CA3037682A1 (en) * | 2016-09-21 | 2018-03-29 | The Wistar Institute Of Anatomy And Biology | Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein |
SG11201903400WA (en) | 2016-10-17 | 2019-05-30 | Pfizer | Anti-edb antibodies and antibody-drug conjugates |
US11084859B2 (en) | 2016-10-24 | 2021-08-10 | Orionis Biosciences BV | Targeted mutant interferon-gamma and uses thereof |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EP3546574A4 (en) | 2016-11-28 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN AND POLYPEPTIDE BINDING AREA INCLUDING A TRANSPORT SECTION |
JPWO2018097308A1 (ja) | 2016-11-28 | 2019-10-17 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
CN108250302A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多功能蛋白质 |
CN110573172A (zh) * | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
CN110382525B (zh) | 2017-04-03 | 2023-10-20 | 豪夫迈·罗氏有限公司 | 免疫缀合物 |
PE20191494A1 (es) | 2017-04-03 | 2019-10-21 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15 |
KR20190136076A (ko) | 2017-04-13 | 2019-12-09 | 에프. 호프만-라 로슈 아게 | 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
AU2018274216A1 (en) | 2017-05-24 | 2019-12-12 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
IL299893A (en) | 2017-06-20 | 2023-03-01 | Madrigal Pharmaceuticals Inc | prescribed medications |
WO2018236791A1 (en) | 2017-06-20 | 2018-12-27 | Madrigal Pharmaceuticals, Inc. | COMBINED THERAPIES COMPRISING TARGETED THERAPEUTICS |
CN118126157A (zh) | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
CA3069992A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Clec9a binding agents and use thereof |
WO2019032663A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | PD-1 AND PD-L1 BINDING AGENTS |
JP7347899B2 (ja) | 2017-08-09 | 2023-09-20 | オリオンズ バイオサイエンス インコーポレイテッド | Cd8結合物質 |
MX2020005220A (es) | 2017-11-28 | 2020-08-24 | Chugai Pharmaceutical Co Ltd | Polipeptido que incluye dominio de union al antigeno y seccion de transporte. |
US11518808B2 (en) | 2018-01-12 | 2022-12-06 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
TWI844524B (zh) * | 2018-02-09 | 2024-06-11 | 義大利商費洛根公司 | 靶向edb之il-12組合物 |
WO2019230867A1 (en) | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
JP2021532796A (ja) * | 2018-07-30 | 2021-12-02 | 晋宇 張 | タンパク質ヘテロ二量体およびその使用 |
WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
CN112996904B (zh) * | 2018-09-07 | 2024-08-06 | 南特生物公司 | 刺激hank和nk92mi细胞的靶向il-12治疗和方法 |
SG11202104136YA (en) | 2018-10-23 | 2021-05-28 | Dragonfly Therapeutics Inc | Heterodimeric fc-fused proteins |
RU2708558C1 (ru) * | 2018-12-13 | 2019-12-09 | Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ | Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4 |
CA3133643A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
KR20220012256A (ko) * | 2019-05-24 | 2022-02-03 | 프로비바 테라퓨틱스 (홍콩) 리미티드 | Il-2 조성물 및 이의 사용 방법 |
WO2021001289A1 (en) | 2019-07-02 | 2021-01-07 | F. Hoffmann-La Roche Ag | Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody |
MX2022001799A (es) | 2019-08-15 | 2022-03-11 | Janssen Biotech Inc | Materiales y metodos para fragmentos variables de cadena unica mejorados. |
EP4077397A2 (en) | 2019-12-20 | 2022-10-26 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
CR20220512A (es) | 2020-04-15 | 2022-11-07 | Hoffmann La Roche | Inmunoconjugados |
WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
AU2021393752A1 (en) | 2020-12-04 | 2023-05-18 | F. Hoffmann-La Roche Ag | Ph-dependent mutant interleukin-2 polypeptides |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
EP4304724A1 (en) | 2021-03-09 | 2024-01-17 | F. Hoffmann-La Roche AG | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies |
JP2024508949A (ja) | 2021-03-09 | 2024-02-28 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1標的化il-2変異体イムノコンジュゲートとfap/4-1bb結合分子との併用療法 |
CA3234731A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
CN118139648A (zh) | 2021-10-14 | 2024-06-04 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的替代的PD1-IL7v免疫缀合物 |
CN118284625A (zh) | 2021-11-26 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法 |
EP4440599A1 (en) * | 2022-01-04 | 2024-10-09 | Philogen S.p.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
WO2024153722A1 (en) | 2023-01-20 | 2024-07-25 | F. Hoffmann-La Roche Ag | Immunoconjugates |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DE69428764T2 (de) * | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
US6632928B1 (en) * | 1997-03-05 | 2003-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxins and methods of inducing immune tolerance |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
ES2221717T3 (es) * | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
DK1719528T3 (da) | 2000-02-24 | 2012-01-09 | Philogen Spa | Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner |
WO2001075110A2 (en) * | 2000-03-30 | 2001-10-11 | Dyax Corp. | Mucin-1 specific binding members and methods of use thereof |
RU2272644C2 (ru) * | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
TW200720439A (en) * | 2005-03-25 | 2007-06-01 | Glycart Biotechnology Ag | Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function |
DE602006012667D1 (de) * | 2005-05-11 | 2010-04-15 | Philogen Spa | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 |
US8744844B2 (en) * | 2007-07-06 | 2014-06-03 | Audience, Inc. | System and method for adaptive intelligent noise suppression |
BRPI0709787A2 (pt) | 2006-05-08 | 2011-03-29 | Philogen Spa | citocinas com anticorpos alvejados para terapia |
EP2187971A2 (en) * | 2007-08-01 | 2010-05-26 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
KR20110112301A (ko) * | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
-
2010
- 2010-08-13 KR KR1020127006987A patent/KR20120053042A/ko active Application Filing
- 2010-08-13 MX MX2012002014A patent/MX2012002014A/es active IP Right Grant
- 2010-08-13 SG SG2012010690A patent/SG178443A1/en unknown
- 2010-08-13 PE PE2012000192A patent/PE20120630A1/es not_active Application Discontinuation
- 2010-08-13 EP EP10744911.8A patent/EP2467165B1/en active Active
- 2010-08-13 RU RU2012110127/10A patent/RU2583876C2/ru active
- 2010-08-13 CA CA2769619A patent/CA2769619C/en active Active
- 2010-08-13 KR KR1020157019073A patent/KR101588598B1/ko active IP Right Grant
- 2010-08-13 AU AU2010285071A patent/AU2010285071A1/en not_active Abandoned
- 2010-08-13 AR ARP100102987A patent/AR077879A1/es unknown
- 2010-08-13 CN CN201080046453.8A patent/CN102573922B/zh active Active
- 2010-08-13 WO PCT/EP2010/061810 patent/WO2011020783A2/en active Application Filing
- 2010-08-13 ES ES10744911.8T patent/ES2534085T3/es active Active
- 2010-08-13 JP JP2012525147A patent/JP5764127B2/ja active Active
- 2010-08-16 TW TW099127335A patent/TW201119672A/zh unknown
- 2010-08-17 US US12/857,882 patent/US8945571B2/en active Active
-
2011
- 2011-12-29 CO CO11181029A patent/CO6430436A2/es not_active Application Discontinuation
-
2012
- 2012-01-20 CR CR20120042A patent/CR20120042A/es unknown
- 2012-01-30 MA MA34588A patent/MA33717B1/fr unknown
- 2012-01-30 IL IL217844A patent/IL217844A0/en unknown
- 2012-01-31 ZA ZA2012/00767A patent/ZA201200767B/en unknown
- 2012-02-16 EC ECSP12011685 patent/ECSP12011685A/es unknown
- 2012-10-11 HK HK12110035.2A patent/HK1169318A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US8945571B2 (en) | 2015-02-03 |
MX2012002014A (es) | 2012-06-13 |
IL217844A0 (en) | 2012-03-29 |
CN102573922B (zh) | 2015-08-05 |
JP5764127B2 (ja) | 2015-08-12 |
SG178443A1 (en) | 2012-04-27 |
JP2013502209A (ja) | 2013-01-24 |
EP2467165B1 (en) | 2015-01-07 |
ZA201200767B (en) | 2014-07-30 |
MA33717B1 (fr) | 2012-11-01 |
CA2769619A1 (en) | 2011-02-24 |
CR20120042A (es) | 2012-03-22 |
CO6430436A2 (es) | 2012-04-30 |
RU2583876C2 (ru) | 2016-05-10 |
KR20150088328A (ko) | 2015-07-31 |
TW201119672A (en) | 2011-06-16 |
HK1169318A1 (zh) | 2013-01-25 |
CA2769619C (en) | 2019-04-30 |
AU2010285071A1 (en) | 2012-02-02 |
WO2011020783A3 (en) | 2011-04-28 |
WO2011020783A2 (en) | 2011-02-24 |
ECSP12011685A (es) | 2012-03-30 |
RU2012110127A (ru) | 2013-09-27 |
KR20120053042A (ko) | 2012-05-24 |
AR077879A1 (es) | 2011-09-28 |
US20110064751A1 (en) | 2011-03-17 |
CN102573922A (zh) | 2012-07-11 |
ES2534085T3 (es) | 2015-04-17 |
KR101588598B1 (ko) | 2016-01-29 |
EP2467165A2 (en) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120630A1 (es) | Inmunoconjugados dirigidos | |
CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
CU24663B1 (es) | Dominio de unión a antígeno anti-trbc1, receptor de antígeno quimérico, anticuerpo y acoplador biespecífico de células t que comprenden el mismo | |
CL2017000250A1 (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
TR201903507T4 (tr) | Boru hatlarında izleme nesneleri. | |
PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
CR20120371A (es) | Antagonistas de pcsk9 | |
UA104459C2 (uk) | Антитіла проти fgfr3 і способи їх застосування | |
EA201100268A1 (ru) | Вакцина | |
EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
CL2009000260A1 (es) | Antagonista de pcsk9 que comprende un dominio cdr3 de la region variable de la cadena liviana y pesada, el cual inhibe la captacion celular del ldl, composicion farmaceutica que comprende dicho antagonista, uso de este, secuencia nucleotidica que codifica el antagonista, vector y celula huesped que la comprende. | |
CL2007003771A1 (es) | Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an | |
CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
EP2569330A4 (en) | CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF | |
CL2011002681A1 (es) | Inmunoconjugado que comprende un agente citotoxico y un anticuerpo humano o humanizado o su fragmento de union a antigeno especifico para mesotelina y que exhibe union invariable a ella; composicion farmaceutica que lo comprende; y su uso para tratar un transtorno o afeccion asociado con la presencia indeseada de mesotelina. | |
CL2013003214A1 (es) | Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol. | |
AR058325A1 (es) | Anticuerpos anti mn y metodos para su utilizacion | |
AR074427A1 (es) | Composiciones estables de anticuerpos y metodos para estabilizarlas | |
NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
NO20083147L (no) | Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse | |
BRPI0923199A2 (pt) | métodos e composições para detecção de anticorpos com fixação de complemento. | |
MX2009005414A (es) | Formulaciones liquidas de anticuerpo antirrabico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |